Literature DB >> 11586958

Vaccines and vaccination.

G Ada1.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11586958     DOI： 10.1056/NEJMra011223

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  57 in total

1.  [30 years of global eradication of smallpox - observations on immunization in Austria].

Authors:  Michael Kunze
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

2.  Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.

Authors:  Hiroyuki Kayamuro; Yasuo Yoshioka; Yasuhiro Abe; Shuhei Arita; Kazufumi Katayama; Tetsuya Nomura; Tomoaki Yoshikawa; Ritsuko Kubota-Koketsu; Kazuyoshi Ikuta; Shigefumi Okamoto; Yasuko Mori; Jun Kunisawa; Hiroshi Kiyono; Norio Itoh; Kazuya Nagano; Haruhiko Kamada; Yasuo Tsutsumi; Shin-ichi Tsunoda
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

3.  Pneumococcal meningitis: clinical outcomes in a pre-vaccine era at a Dublin paediatric hospital, 1999-2007.

Authors:  J M Lucey; P Gavin; M Cafferkey; K M Butler
Journal:  Ir J Med Sci       Date:  2010-11-12       Impact factor: 1.568

4.  Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae.

Authors:  Patrick M Meyer Sauteur; Adrianus C J M de Bruijn; Catarina Graça; Anne P Tio-Gillen; Silvia C Estevão; Theo Hoogenboezem; Rudi W Hendriks; Christoph Berger; Bart C Jacobs; Annemarie M C van Rossum; Ruth Huizinga; Wendy W J Unger
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

5.  Detection and characterization of bacterial polysaccharides in drug-resistant enterococci.

Authors:  Liaqat Ali; Hubert E Blum; Türkân Sakιnç
Journal:  Glycoconj J       Date:  2019-06-22       Impact factor: 2.916

6.  Mucosal adjuvant properties of the Shigella invasin complex.

Authors:  Robert W Kaminski; K Ross Turbyfill; Edwin V Oaks
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

7.  [Prevention in the elderly: position paper on pneumococcal vaccinations. Results of an expert workshop on 15 November 2013 in Cologne, Germany].

Authors:  G Fätkenheuer; A Kwetkat; M W Pletz; J Schelling; R-J Schulz; M van der Linden; T Welte
Journal:  Z Gerontol Geriatr       Date:  2014-06       Impact factor: 1.281

8.  Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥ 50 years of age in Mexico.

Authors:  Juan Carlos Tinoco; Christine Juergens; Guillermo M Ruiz Palacios; Jorge Vazquez-Narvaez; Hermann Leo Enkerlin-Pauwells; Vani Sundaraiyer; Sudam Pathirana; Elena Kalinina; William C Gruber; Daniel A Scott; Beate Schmoele-Thoma
Journal:  Clin Vaccine Immunol       Date:  2014-12-10

9.  Influenza-related hospitalization and ED visits in children less than 5 years: 2000-2011.

Authors:  Astride Jules; Carlos G Grijalva; Yuwei Zhu; H Keipp Talbot; John V Williams; Katherine A Poehling; Sandra S Chaves; Kathryn M Edwards; William Schaffner; David K Shay; Marie R Griffin
Journal:  Pediatrics       Date:  2014-12-08       Impact factor: 7.124

Review 10.  Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection.

Authors:  Malcolm J M Darkes; Greg L Plosker
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.